FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
After reviewing Bausch & Lomb’s response to its observations, the FDA questioned whether the company is committed to implementing significant design remediations.
Bausch + Lomb
Global eye health company developing, manufacturing and marketing vision care products, contact lenses, ophthalmic pharmaceuticals and surgical devices.
Company Info
Upcoming Milestones & Key Dates
2026-Q4
Clinical
Dry eye combo Phase 3 data readout
2027-Q1
Regulatory
Potential EU filing for dry eye combo
Clinical Development Pipeline
NOV03
Target: Meibomian glandsLumify
Target: Alpha-adrenergic agonistBrimonidine/Brinzolamide
Target: Alpha-2 agonist/CAIRecent News
Leadership Team
Brent Saunders
Chairman and CEO
Sam Eldessouky
CFO
Joe Gordon
President, Global Vision Care